FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Motus GI Holdings, Inc., (NASDAQ:MOTS) ("Motus GI" or the "Company"), a medical technology company dedicated to improving clinical outcomes and enhancing the cost-efficiency of colonoscopy, announced today the appointment of Jeff Hutchison as Vice President of U.S. Sales and Commercial Operations. Mr. Hutchison will be responsible for building Motus GI’s U.S. sales organization and driving the Company’s pre-launch commercial activities ahead of the planned launch of the Pure-Vu® System into the inpatient market in 2019. The Pure-Vu® System, the Company’s flagship, FDA-cleared medical device system, enables physicians to rapidly cleanse the colon during the colonoscopy procedure to facilitate improved visualization and enable a quality exam. Challenges with bowel preparation for inpatient colonoscopy represent a significant area of unmet need that directly affects clinical outcomes and increases the cost of care in a market segment that comprises approximately 1.5 million annual procedures in the U.S. and approximately 4 million annual procedures worldwide.
“The appointment of Jeff Hutchison as our VP of U.S. Sales and Commercial Operations is a critical step in our strategic roadmap to the commercial launch of the Pure-Vu® System in the inpatient colonoscopy market,” commented Mark Pomeranz, CEO of Motus GI. “Jeff is an experienced and senior sales leader in the GI space who was a key player in the launch and commercial build out of BÂRRX prior to its acquisition by Covidien as well as its continued growth under Covidien and then Medtronic. He knows how to build and lead a sales organization to drive new market opportunities in the GI space and that is exactly why he is joining Motus GI now.”
Mr. Hutchison joins Motus GI following over 25 years of executive sales leadership and new market development experience in the medical device industry. He most recently served as Vice President of U.S. Sales for Bio2 Medical. Prior to that, he served as Area Vice President of Sales for Medtronic GI Solutions (NYSE: MDT) where he led the Western Division of Medtronic’s GI business, managed the integration of two major acquisitions and led the growth of the organization from 33 territories and 4 regions to 135 territories and 18 regions. Previously, he served as Director of U.S. Sales for BÂRRX Medical, where he led the U.S. sales organization and drove commercialization of BÂRRX’s endoscopic treatment devices for Barrett’s Esophagus. Mr. Hutchison was an integral part of the BÂRRX’s acquisition team when it was purchased by Covidien in 2011 (Covidien was later acquired by Medtronic). During that time, he oversaw the hiring of 50 professionals. Prior to BÂRRX, Mr. Hutchison spent 17 years at Boston Scientific (NYSE: BSX) in a variety of sales, sales management and market development roles in the endoscopy and cardiology divisions.
“The Pure-Vu® System presents an opportunity to deliver significant clinical and economic benefits not only for patients but for all stakeholders involved in colonoscopy for hospitalized patients including physicians, nursing staff and hospital administrators,” said Hutchison. “I am thrilled to be joining Motus GI at this time when I can play a pivotal role in building our commercial organization and driving our commercialization plan focused on the inpatient hospital market. I am really looking forward to bringing this product to market and seeing us realize its potential.”
About Motus GI and the Pure-Vu® System
Motus GI Holdings, Inc. is a medical technology company, with subsidiaries in the U.S. and Israel, dedicated to improving clinical outcomes and enhancing the cost-efficiency of colonoscopy. The Company’s flagship product is the Pure-Vu® System, a 510(k) U.S. Food and Drug Administration cleared medical device indicated to help facilitate the cleaning of a poorly prepared colon during the colonoscopy procedure. The device integrates with standard colonoscopes to enable cleaning during the procedure while preserving standard procedural workflow and techniques. The Pure-Vu® System has received CE mark approval in Europe. The Pure-Vu® System is currently being introduced on a pilot basis in the U.S. market, and the Company is planning to initiate a full commercial launch focused on the inpatient colonoscopy market in the U.S. and select international markets in 2019. Challenges with bowel preparation for inpatient colonoscopy represent a significant area of unmet need that directly affects clinical outcomes and increases the cost of care in a market segment that comprises approximately 1.5 million annual procedures in the U.S. and approximately 4 million annual procedures worldwide. Motus GI believes the Pure-Vu® System may improve outcomes and lower costs for hospitals by reducing the time to successful colonoscopy, minimizing delayed and aborted procedures, and improving the quality of an exam. In clinical studies to date, the Pure-Vu® System significantly increased the number of patients with an adequate cleansing level, according to the Boston Bowel Preparation Scale Score, a validated assessment instrument.
This press release contains certain forward-looking statements. Forward-looking statements are based on the Company's current expectations and assumptions. The Private Securities Litigation Reform Act of 1995 provides a safe-harbor for forward-looking statements. These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms, including without limitation, risks inherent in the development and commercialization of potential products, uncertainty in the timing and results of clinical trials or regulatory approvals, maintenance of intellectual property rights or other risks discussed in the Company’s Form 10-K filed on March 28, 2018, and its other filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.